Research question
Among adults with melanoma, how does the incidence of myocarditis compare between dual-agent PD-1/CTLA-4 blockade and single-agent PD-1 inhibition?
Summary
Although dual-agent immunotherapies have significantly improved survival rates for advanced melanoma, this hyper-activation of the immune system introduces profound clinical trade-offs. Chief among these is treatment-induced myocarditis, a highly fatal inflammation of the heart muscle that presents a critical challenge to patient safety. Researchers are working to balance aggressive tumor management with long-term cardiovascular preservation as combination therapies become more widely adopted.
This project will conduct a systematic literature review to compare the precise incidence, onset timelines, and mortality rates of myocarditis between dual-agent and single-agent checkpoint blockades. By aggregating and analyzing recent clinical data, this study will evaluate the statistical risks of combination therapies, identify patient-specific risk factors, and examine emerging clinical guidelines for managing cardiotoxicity in melanoma care.
Why it matters
Combination immunotherapy is becoming more common in melanoma care, and myocarditis is one of its most serious side effects. Bringing the reported incidence, timing and outcomes together in one place can help clinicians and drug developers weigh the benefit of combination therapy against its cardiac risk.